COMMUNIQUÉS West-GlobeNewswire

argenx to Report First Quarter 2026 Financial Results and Business Update on May 7, 2026
30/04/2026
April 30, 2026 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it [...]
Nicox Provides Full Year 2025 Financial Results and Corporate Update
30/04/2026
Press Release Nicox Provides Full Year 2025 Financial Results and Corporate Update Revenue of €16.8 million (€7.9 million in 2024) Net loss significantly reduced to €2.4 million (€22.4 million in 2024) NCX 470 U.S. New [...]
Valneva Announces the Successful Completion of an €84 million Reserved Offering
30/04/2026
Valneva Announces the Successful Completion of an €84 million Reserved Offering Lyon (France), April 30, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (“ Valneva ” or the “ Company ”), a specialty vaccine [...]
Nicox annonce ses résultats financiers 2025 et fait un point sur son activité
30/04/2026
Communiqué de presse Nicox annonce ses résultats financiers 2025 et fait un point sur son activité Chiffre d’affaires de 16,8 millions d’euros (7,9 millions d’euros en 2024) Perte nette significativement réduite à 2,4 [...]
Valneva annonce le succès d’une Offre Réservée d’un montant de 84 millions d’euros
30/04/2026
Lyon (France), le 30 avril 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) (« Valneva » ou la « Société »), société spécialisée dans les vaccins, annonce le succès d’une offre réservée d’un montant de 84 millions [...]
Vaccinex Reports 2025 Annual Financial Results
30/04/2026
ROCHESTER, N.Y., April 29, 2026 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (OTCMKTS:VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in Alzheimer’s, Huntington’s disease, and [...]
Avalyn Announces Pricing of Upsized Initial Public Offering
30/04/2026
BOSTON, April 29, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. (Nasdaq: AVLN) (“Avalyn”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare [...]
Mesoblast Reports Ryoncil® Net Revenues of US$30.3m and Improved Net Operating Cash Spend for the Quarter to US$4.1 Million
30/04/2026
Achieved Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Activity Report for Quarter Ended March 31, 2026 (Appendix 4C) NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited ( [...]
RxSight, Inc. to Present at the Bank of America Healthcare Conference
29/04/2026
ALISO VIEJO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., today announced plans to participate in the upcoming Bank of America Healthcare Conference. Management is scheduled to participate in a fireside [...]
Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
29/04/2026
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
AVITA Medical Announces TGA Certification in Australia and Medsafe WAND Listing in New Zealand for RECELL GO
29/04/2026
RECELL GO ® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both markets RECELL GO is AVITA Medical’s next-generation system that automates and standardizes the preparation [...]
Crescent Biopharma Reports First Quarter 2026 Financial Results and Recent Business Highlights
29/04/2026
ASCEND Phase 1/2 global clinical trial ongoing, evaluating CR-001, a PD-1 x VEGF bispecific antibody, in multiple solid tumor types in first-line and previously treated patients; first ADC combination trial with CR-001 [...]
MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026
29/04/2026
ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and [...]
Seer to Report First Quarter 2026 Financial Results on May 13, 2026
29/04/2026
REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the [...]
LogicMark, Inc. to Announce First Quarter 2026 Financial Results on May 13, 2026
30/04/2026
LOUISVILLE, Ky., April 29, 2026 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC: LGMK), a provider of emergency response systems, health communications devices, and technology for the growing personal safety and care economy, [...]
Relay Therapeutics to Announce First Quarter 2026 Financial Results and Corporate Highlights on May 5, 2026
29/04/2026
CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies for patients [...]
Teladoc Health Reports First Quarter 2026 Results
29/04/2026
NEW YORK, April 29, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, today reported financial results for the three months ended March 31, 2026 (“First Quarter 2026”). [...]
Serotonin Centers Opens Second North Texas Location in Fort Worth, Expanding Physician-Led Longevity Care
29/04/2026
New Center Builds on Strong Demand in Dallas–Fort Worth for Hormone Optimization, Medical Weight Loss and Proactive Health FORT WORTH, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Serotonin Centers, a national leader in [...]
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
29/04/2026
TLX597-Tx is a PSMA 1 -targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. OPTIMAL-PSMA 2 initial dosimetry data demonstrate [...]

Pages